1. Healthcare

30 Jan 2015
Page
SWOG Current and Projected Accrual by Committee
Data as of 30 Jan 2015
Therapeutic Registrations Only (Txca=Y)
8% of Calendar Year is Past
Base Accrual
Committee
2010
--------- -----------BREAST
1558
ERLYTX
76
GI
476
GU
450
GYN
57
LEUK
150
LUNG
524
LYMPH
172
MELAN
55
MMYEL
147
OTHER
0
Other
0
-----------3665
Projected
12 Month
2015 Percentage Projected
Increase
Accrual
Increase
Accrual
of Base
2015 <Decrease>
Last <Decrease>
to date
Accrual
Accrual from Base 12 Months from Base
---------- ---------- --------- ---------- --------- ---------121
8%
1472
<86>
1427
<131>
0
0%
0
<76>
3
<73>
38
8%
462
<14>
374
<102>
77
17%
937
487
996
546
0
0%
0
<57>
1
<56>
42
28%
511
361
600
450
25
5%
304
<220>
216
<308>
12
7%
146
<26>
87
<85>
3
5%
37
<19>
131
76
16
11%
195
48
136
<11>
1
12
12
33
33
0
0
0
1
1
------------------ ---------- --------- ---------335
4076
411
4005
340
1
30 Jan 2015
Page
SWOG Current and Projected Accrual by Committee
Data as of 30 Jan 2015
Non-Therapeutic Registrations Only
8% of Calendar Year is Past
Base Accrual
Committee
2010
--------- -----------BREAST
37
CCD
0
GI
0
GU
0
LEUK
69
LUNG
43
LYMPH
53
Lung
0
MMYEL
92
PREV
0
SURV
0
SXQOL
878
-----------1172
Projected
12 Month
2015 Percentage Projected
Increase
Accrual
Increase
Accrual
of Base
2015 <Decrease>
Last <Decrease>
to date
Accrual
Accrual from Base 12 Months from Base
---------- ---------- --------- ---------- --------- ---------1
3%
12
<25>
47
10
0
0
0
212
212
0
0
0
3
3
4
49
49
50
50
0
0%
0
<69>
0
<69>
24
56%
292
249
158
115
0
0%
0
<53>
0
<53>
4
49
49
5
5
0
0%
0
<92>
0
<92>
4
49
49
88
88
0
0
0
11
11
34
4%
414
<464>
260
<618>
------------------ ---------- --------- ---------71
864
<308>
834
<338>
1
30 Jan 2015
Page
SWOG Current and Projected Accrual by Committee
Data as of 30 Jan 2015
All Initial Registrations
8% of Calendar Year is Past
Base Accrual
Committee
2010
--------- -----------BREAST
1595
CCD
0
ERLYTX
76
GI
476
GU
450
GYN
57
LEUK
219
LUNG
567
LYMPH
225
Lung
0
MELAN
55
MMYEL
239
OTHER
0
Other
0
PREV
0
SURV
0
SXQOL
878
0
-----------4837
Projected
12 Month
2015 Percentage Projected
Increase
Accrual
Increase
Accrual
of Base
2015 <Decrease>
Last <Decrease>
to date
Accrual
Accrual from Base 12 Months from Base
---------- ---------- --------- ---------- --------- ---------122
8%
1484
<111>
1474
<121>
0
0
0
212
212
0
0%
0
<76>
3
<73>
38
8%
462
<14>
377
<99>
81
18%
986
536
1046
596
0
0%
0
<57>
1
<56>
42
19%
511
292
600
381
49
9%
596
29
374
<193>
12
5%
146
<79>
87
<138>
4
49
49
5
5
3
5%
37
<19>
131
76
16
7%
195
<44>
136
<103>
1
12
12
33
33
0
0
0
1
1
4
49
49
88
88
0
0
0
11
11
34
4%
414
<464>
260
<618>
0
0
0
3
3
------------------ ---------- --------- ---------406
4940
103
4842
5
1
30 Jan 2015
Page
SWOG Current and Projected Accrual by Committee
Data as of 30 Jan 2015
Therapeutic Registrations by SWOG Institutions Only (Txca=Y)
8% of Calendar Year is Past
Base Accrual
Committee
2010
--------- -----------BREAST
1012
ERLYTX
76
GI
418
GU
375
GYN
57
LEUK
122
LUNG
441
LYMPH
129
MELAN
55
MMYEL
85
OTHER
0
Other
0
-----------2770
Projected
12 Month
2015 Percentage Projected
Increase
Accrual
Increase
Accrual
of Base
2015 <Decrease>
Last <Decrease>
to date
Accrual
Accrual from Base 12 Months from Base
---------- ---------- --------- ---------- --------- ---------53
5%
645
<367>
782
<230>
0
0%
0
<76>
3
<73>
31
7%
377
<41>
315
<103>
42
11%
511
136
561
186
0
0%
0
<57>
1
<56>
21
17%
256
134
347
225
19
4%
231
<210>
155
<286>
10
8%
122
<7>
70
<59>
2
4%
24
<31>
130
75
11
13%
134
49
103
18
1
12
12
33
33
0
0
0
1
1
------------------ ---------- --------- ---------190
2312
<458>
2501
<269>
1
30 Jan 2015
Page
SWOG Current and Projected Accrual by Committee
Data as of 30 Jan 2015
Non-Therapeutic Registrations by SWOG Institutions Only
8% of Calendar Year is Past
Base Accrual
Committee
2010
--------- -----------BREAST
10
CCD
0
GI
0
GU
0
LEUK
69
LUNG
30
LYMPH
53
Lung
0
MMYEL
92
PREV
0
SURV
0
SXQOL
740
-----------994
Projected
12 Month
2015 Percentage Projected
Increase
Accrual
Increase
Accrual
of Base
2015 <Decrease>
Last <Decrease>
to date
Accrual
Accrual from Base 12 Months from Base
---------- ---------- --------- ---------- --------- ---------0
0%
0
<10>
46
36
0
0
0
212
212
0
0
0
3
3
4
49
49
50
50
0
0%
0
<69>
0
<69>
15
50%
183
153
85
55
0
0%
0
<53>
0
<53>
4
49
49
5
5
0
0%
0
<92>
0
<92>
2
24
24
71
71
0
0
0
11
11
30
4%
365
<375>
203
<537>
------------------ ---------- --------- ---------55
669
<325>
686
<308>
1
30 Jan 2015
Page
SWOG Current and Projected Accrual by Committee
Data as of 30 Jan 2015
All Initial Registrations by SWOG Institutions
8% of Calendar Year is Past
Base Accrual
Committee
2010
--------- -----------BREAST
1022
CCD
0
ERLYTX
76
GI
418
GU
375
GYN
57
LEUK
191
LUNG
471
LYMPH
182
Lung
0
MELAN
55
MMYEL
177
OTHER
0
Other
0
PREV
0
SURV
0
SXQOL
740
0
-----------3764
Projected
12 Month
2015 Percentage Projected
Increase
Accrual
Increase
Accrual
of Base
2015 <Decrease>
Last <Decrease>
to date
Accrual
Accrual from Base 12 Months from Base
---------- ---------- --------- ---------- --------- ---------53
5%
645
<377>
828
<194>
0
0
0
212
212
0
0%
0
<76>
3
<73>
31
7%
377
<41>
318
<100>
46
12%
560
185
611
236
0
0%
0
<57>
1
<56>
21
11%
256
65
347
156
34
7%
414
<57>
240
<231>
10
5%
122
<60>
70
<112>
4
49
49
5
5
2
4%
24
<31>
130
75
11
6%
134
<43>
103
<74>
1
12
12
33
33
0
0
0
1
1
2
24
24
71
71
0
0
0
11
11
30
4%
365
<375>
203
<537>
0
0
0
3
3
------------------ ---------- --------- ---------245
2981
<783>
3190
<574>
1
30 Jan 2015
Page
SWOG Current and Projected Accrual by Committee
Data as of 30 Jan 2015
Initial Registrations to Cancer Control Studies
8% of Calendar Year is Past
Base Accrual
Committee
2010
--------- -----------BREAST
65
CCD
0
GI
81
GU
215
LEUK
0
LUNG
53
LYMPH
7
MELAN
0
MMYEL
0
OTHER
0
Other
0
PREV
0
SURV
0
SXQOL
878
-----------1299
Projected
12 Month
2010 Percentage Projected
Increase
Accrual
Increase
Accrual
of Base
2010 <Decrease>
Last <Decrease>
to date
Accrual
Accrual from Base 12 Months from Base
---------- ---------- --------- ---------- --------- ---------115
177%
1399
1334
1374
1309
0
0
0
212
212
7
9%
85
4
59
<22>
9
4%
110
<106>
84
<131>
4
49
49
62
62
0
0%
0
<53>
3
<50>
3
43%
37
30
27
20
0
0
0
115
115
3
37
37
30
30
1
12
12
15
15
0
0
0
1
1
4
49
49
88
88
0
0
0
11
11
34
4%
414
<464>
260
<618>
------------------ ---------- --------- ---------180
2190
891
2341
1042
1
30 JAN 2015
Southwest Oncology Group
Open and Temporarily Closed Studies
Stat
Comm. Phase Study
Center
------ ------ ---------------------------------------- -----BREAST II
E3108 CYP2D6 Activity&SingleAgTamox
ECOG-A
CRIN
GI
Monthly
Open
Months Total Accrual Accrual
Date
Open
Regs
Goal
Rate
---------- ------- ------ ------- -------08-OCT-10
17
.0
Date of
Expected Closure or
Temporary Closure
--------------------
Z11102 Breast Conserv. Surgery for MIBC
ALLIAN
CE
PACCT-1 Assess of Ca Clinical Tests
ECOG-A 24-APR-06
CRIN
1712
B43 Breast, DCIS, HER2+, RT +/- Tras
B47 Chemo vs Chemo + Trastuzumab
S1007 Breast,Adj,N1,Endocrine+/-Chemo
E2108 Early Local Tx for Int Prim Tum
NRG
NRG
SWOG
ECOG-A
CRIN
66
153
3217
44
S1207 Brst,Adj,Endocrine+/-Everolimus
A011106 Breast, Neoadj, ALTERNATE study
SWOG
03-SEP-13
ALLIAN 15-FEB-14
CE
16
255
5
3500
24.3 Feb-2026
.7
S1222 Brst,Fulv. +/- Ever. +/- Anastr.
A011202 Breast, Nodal XRT +/- ALND
SWOG
09-MAY-14
ALLIAN
CE
8
32
7
840
3.8 > 15 Yrs
B51 Breast, Regional Nodal XRT
B52 Breast, Neoadj TCHP +/- AI
R1005 RTOG-1005
NRG
NRG
NRG
2
3
17
OTHER
E1Z11 Brst,Genetic Predictors of AIMSS
ECOG-A 10-MAY-13
CRIN
98
1.8
III
A011104 Preoperative Breast MRI
ALLIAN 21-FEB-14
CE
2
.0
OTHER
S1204 Prevalence HIV,HBV,HCV+Cost Eff
SWOG
29-AUG-13
17
312
3061
.0 > 15 Yrs
I-II
S1313 Panc,Met,mFolfirinox+/-PEGPH20
SWOG
06-JAN-14
12
7
172
.8 > 15 Yrs
III
CCD
Page
2
22-NOV-08
07-JAN-11
15-JAN-11
28-FEB-11
48
.0
4000
.8
2.7
83.0 Oct-2015
1.5
1
30 JAN 2015
Southwest Oncology Group
Open and Temporarily Closed Studies
Page
Monthly
Stat
Open
Months Total Accrual Accrual
Comm. Phase Study
Center Date
Open
Regs
Goal
Rate
------ ------ ---------------------------------------- ------ ---------- ------- ------ ------- -------GI
GU
II
S1201 Gas/Esoph/GEJ, Adv, ERCC1-based
E7208 CRC,Adv, Irino/Cet+/-Ramucirumab
SWOG
01-MAR-12
ECOG-A 18-JUL-12
CRIN
34
E2211 Panc, Adv, Temozolomide +/- Cape
ECOG-A 18-APR-13
CRIN
27
1.7
A021202 Carcinoid, Pazopanib vs Placebo
ALLIAN 08-MAY-13
CE
16
1.5
S1310 Biliary,RefAdv,GSK1120212vsChemo
S1406 CRC,Met,BRAF mut,Irino+Cetux±Vem
C80803 Esoph, PET-directed combined Tx
SWOG
15-FEB-14
SWOG
13-NOV-14
ALLIAN
CE
II-III N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX
ALLIAN 13-JAN-12
CE
50
3.3
III
R0848 Panc, Adj, Erlotinib v ChemoRT
C80802 HCC, Adv, Sorafenib+/- Doxorub
NRG
08-DEC-09
ALLIAN 22-FEB-10
CE
16
42
.0
.3
C80702 Adj FOLFOX+Celecoxib or Placebo
ALLIAN 22-JUN-10
CE
443
7.2
R1010 Esoph,HER2,TrimodalTx+/-Trastu
NRG
07-JAN-11
5
.0
II
S1314 Blad, COXEN Neoadj. Chemo + Cyst
SWOG
11-JUL-14
III
C90203 Pros, Surgery +/- Neoadj Chemo
ALLIAN 22-DEC-06
CE
146
1.3
C70807 Pros, MEAL Study
ALLIAN 21-JAN-11
CE
138
4.2
S0931 Renal, EVEREST
S1011 Blad, Standard vs Extended LND
E2810 Renal, Pazopanib vs Placebo
SWOG
01-APR-11
SWOG
01-AUG-11
ECOG-A 17-APR-12
11
2
6
45
41
197
3
36
8
5
4
1052
403
25
225
89
78
212
1218
620
Date of
Expected Closure or
Temporary Closure
--------------------
6.8 May-2015
.5
4.5 Dec-2015
.7 > 15 Yrs
35.7 May-2015
10.8 Sep-2016
.5
2
30 JAN 2015
Southwest Oncology Group
Open and Temporarily Closed Studies
Page
Monthly
Stat
Open
Months Total Accrual Accrual
Comm. Phase Study
Center Date
Open
Regs
Goal
Rate
------ ------ ---------------------------------------- ------ ---------- ------- ------ ------- -------CRIN
GU
III
S1216 Pros Adv, ADT +/- TAK-700 or Bic
SWOG
01-MAR-13
A031201 CRMPC, Enza +/- (Abira + Predni) ALLIAN 22-NOV-13
CE
R0534
R0815
R0924
R1115
LEUK
LUNG
Pros,
Pros,
Pros,
Pros,
PBRT +/- NC-STAD +/- PLNRT
dose-esca. RT +/- ADT
NADT+WPRT vs. NADT+P&SV RT
(ADT + RT) +/- TAK-700
22
NRG
NRG
NRG
NRG
609
44
1636
29.7 Nov-2017
4.8
.8 Dec-2017
3
8
3
2
I
S1312 ALL,CD22+,REL/REF,Inotuzumab+CVP
SWOG
01-APR-14
9
8
38
I-II
S1318 ALL, Age 65+, Ph±, Blinatumomab
SWOG
12-JAN-15
0
0
44
II
S0919 Rel AML: Pravastatin+Ida+Ara-C
C10701 Ph+ ALL, age 50+, Dasatinib+HCT
SWOG
15-AUG-09
ALLIAN 22-MAY-12
CE
65
94
13
110
III
E2905 MDS, Len vs Len + Epo
ECOG-A 09-FEB-09
CRIN
61
1.3
E2906 AML,age 60+,Clo vs Dauno+Cy
ECOG-A 24-FEB-11
CRIN
75
1.8
S1203 AML, Age 18-60, 7+3/IA/IA+V
A041202 CLL,65+,Ben+Rtx vs Ibrut±Rtx
SWOG
08-FEB-13
ALLIAN 22-OCT-13
CE
E1910 BCR-ABL-neg B ALL, blinatumomab
ECOG-A 23-DEC-13
CRIN
15
2.0
E1912 CLL, age 18-70, Ibrutinib vs FCR
ECOG-A 07-FEB-14
CRIN
39
3.0
S0905 Mesothem,cediranib+chemo,PhI/II
SWOG
I-II
Date of
Expected Closure or
Temporary Closure
--------------------
15-MAR-10
23
58
548
39
91
784
128
2.2 Aug-2015
1.3
35.2 Jul-2015
5.0
1.7 Nov-2016
3
30 JAN 2015
Southwest Oncology Group
Open and Temporarily Closed Studies
Stat
Comm. Phase Study
Center
------ ------ ---------------------------------------- -----LUNG
II
C30901 Mesothelioma, Maint. Pemtrxd vs ALLIAN
CE
R1306 NSCLC,Adv,ALK/EGFR,TargetAgents
S1300 NSCLC,Adv,Alk+,Pem±Crizotinib
II-III S1400D
S1400C
S1400A
S1400B
III
LYMPH
FGFR: AZD4547 vs Docetaxel
CDK4/6: Palbociclib v Docetaxel
Non-Match: MEDI4736 vs Docetaxel
P13K: GDC-0032 vs Docetaxel
Page
Monthly
Open
Months Total Accrual Accrual
Date
Open
Regs
Goal
Rate
---------- ------- ------ ------- -------22-SEP-11
2
.2
NRG
SWOG
04-NOV-13
01-AUG-14
5
5
0
114
SWOG
SWOG
SWOG
SWOG
15-JUN-14
15-JUN-14
15-JUN-14
15-JUN-14
7
7
7
7
4
13
36
4
318
328
400
420
.3
.0 > 15 Yrs
.7
2.2
6.0
.7
C140503 NSCL, Lobect v Sublobar resect
ALLIAN 09-JUL-07
CE
20
.2
C30610 SCLC, Thoracic RT
ALLIAN 21-MAR-08
CE
48
.2
S0819 NSCLC, ADV, CHEMO/BEV +/-CET
C30801 NSCLC, Adv, Select COX-2 Inhib
SWOG
15-JUL-09
ALLIAN 22-JUL-10
CE
1333
34
N107C SRS vs WBRT on Resected Met Dz
ALLIAN 08-JUL-11
CE
0
C30607 NSCL,Adv Main Sunitinib v Placbo
ALLIAN
CE
2
E5508 NSCL,Adv,Main Bev,Pem or Bev+Pem
ECOG-A
CRIN
44
OTHER
S1400 SCCA,Adv,
SWOG
II
Biomarker Master
15-JUN-14
7
158
S1001 DLBCL, I-II, PET-Adapted Therapy
9177 NHL, dose-adj. EPOCH+/-Rituximab
E1411 MCL, RB+R, RBV+R, RB+LR, RBV+LR
SWOG
15-JUL-11
NCIMET 13-APR-12
ECOG-A 08-JUN-12
CRIN
42
110
18
40
C51101 CNS, myelo/non-myelo chemo, PhII
ALLIAN 22-JUN-12
CE
3
Date of
Expected Closure or
Temporary Closure
--------------------
1700
> 15 Yrs
Feb-2027
Jan-2020
> 15 Yrs
Jun-2014 Temp Close
.0
.0
25.5
155
4.0 Dec-2015
.2
1.7
.0
4
30 JAN 2015
Southwest Oncology Group
Open and Temporarily Closed Studies
Stat
Comm. Phase Study
Center
------ ------ ---------------------------------------- -----LYMPH II
E1412 DLBCL, R2CHOP vs RCHOP
ECOG-A
CRIN
Page
Monthly
Open
Months Total Accrual Accrual
Date
Open
Regs
Goal
Rate
---------- ------- ------ ------- -------22-JAN-14
12
1.2
Date of
Expected Closure or
Temporary Closure
--------------------
Lung
OTHER
A151216 ALCHEMIST
ALLIAN
CE
MELAN
I-II
S1221 Melan,Adv,Dab+Tram+GSK2141795
SWOG
II
E2607 Dasatinib in KIT+ pts w/Melanoma
ECOG-A 22-NOV-11
CRIN
S1320 Adv, BRAF mut, Inter v Contin
SWOG
III
E1609 Mel,AdjIpilAntiCTLA4vsInterferon
ECOG-A 08-JUN-11
CRIN
I-II
S1211 MM,High Risk, RVD+/-ELO
SWOG
27-OCT-12
27
50
110
4.2 Mar-2016
II
S1304 MM,relapsed/refractory, CAR+DEX
SWOG
18-OCT-13
15
68
140
6.5 Dec-2015
III
E3A06 Lenalidomide vs Observation
ECOG-A 08-NOV-10
CRIN
18
.7
E1A11 MM, frontline, BLD vs CLD
ECOG-A 22-NOV-13
CRIN
21
2.0
E1311 HNSCC, Adj
ECOG-A
CR
1
ECOG-A
CRIN
3
MMYEL
OTHER
II
Afatinib vs Placebo
E3311 Oroph,Srg + Low or Std IMRT
5
12-JUL-13
22-JUL-14
18
10
70
4
6
9
.2 > 15 Yrs
.0
280
499
1.5 > 15 Yrs
3.2
5
30 JAN 2015
Southwest Oncology Group
Open and Temporarily Closed Studies
Page
Monthly
Stat
Open
Months Total Accrual Accrual
Comm. Phase Study
Center Date
Open
Regs
Goal
Rate
------ ------ ---------------------------------------- ------ ---------- ------- ------ ------- --------
OTHER
III
E3F05 E3F05
ECOG-A 08-OCT-09
CRIN
1
ALLIAN
CE
3
E1305 E1305
ECOG-A
CRIN
32
G0258 Endo, Adv, CDDP+RT->CP vs CP
G0261 OVAR, Adv, CP vs Ifosfamide + P
N0574 N0574
NRG
NRG
ALLIAN
CE
2
1
2
N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC
ALLIAN
CE
1
R0920 HN, ADV, POSTOP IMRT ± CETUXIMAB
R1016 Orophx,p16+,RT+Cis v RT+Cetuxmab
NRG
NRG
3
8
OTHER
G0273 OVAR, Chemo Toxicity in Elderly
NRG
1
Other
I-II
N1174 Bev +/- TRC105 in Bev Naïve GBM
ALLIAN
CE
1
PREV
III
S0820 ColrecStg0-3 Blind DFMO/Sulindac
SWOG
OTHER
A211201 Breast Density, MA.32 companion
ALLIAN
CE
III
S1200 Breast,AI Joint Pain,Acupuncture
SWOG
16-MAY-12
S1202 Duloxetine AI Joint Pain
SWOG
15-MAY-13
A221101 Glioma, Nuvigil/Placebo Fatigue ALLIAN
A091105 Desmoid,
SXQOL
Sorafenib vs Placebo
01-MAR-13
22
38
Date of
Expected Closure or
Temporary Closure
--------------------
.0
1488
3.0 > 15 Yrs
228
294
6.0 Apr-2016
14.3 Sep-2015
12
32
20
134
170
6
6
30 JAN 2015
Southwest Oncology Group
Open and Temporarily Closed Studies
Page
Monthly
Stat
Open
Months Total Accrual Accrual
Comm. Phase Study
Center Date
Open
Regs
Goal
Rate
------ ------ ---------------------------------------- ------ ---------- ------- ------ ------- -------CE
SXQOL
III
SCUSF806 Breast, Adj, Cardiotoxicity
SCUSF
OTHER
S1013 Validation Study of FACT-EGFRI
SWOG
E2511
ECOG-A
CR
Date of
Expected Closure or
Temporary Closure
--------------------
19
15-NOV-11
38
90
156
3.7 Jun-2016
3
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.
7
30 JAN 2015Southwest Oncology Group
Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center
Int
Phase Comm. grp
------ ------ --OTHER BREAST Y
Stat
Center Study
NCIPROTO
------ ----------------------------------------- -------------ECOG-A E1Z11 Brst,Genetic Predictors of AIMSS
E1Z11
CRIN
Ca
Cntrl Temp
Study Close
----- ----Y
CCD
Y
SWOG
S1204 Prevalence HIV,HBV,HCV+Cost Eff
S1204
Y
LUNG
Y
SWOG
S1400 SCCA,Adv,
S1400
N
Lung
Y
ALLIAN A151216 ALCHEMIST
CE
A151216
N
OTHER
Y
NRG
GOG-0273
Y
PREV
N
Y
Biomarker Master
G0273 OVAR, Chemo Toxicity in Elderly
S0000B SELECT Eye Endpoints (SEE)
ALLIAN A211201 Breast Density, MA.32 companion
CE
Y
A211201
Y
SXQOL
N
S1013 Validation Study of FACT-EGFRI
Y
I
LEUK
N
S1312 ALL,CD22+,REL/REF,Inotuzumab+CVP
N
I-II
GI
N
S1313 Panc,Met,mFolfirinox+/-PEGPH20
N
LEUK
Y
LUNG
N
S0905 Mesothem,cediranib+chemo,PhI/II
N
MELAN
N
S1221 Melan,Adv,Dab+Tram+GSK2141795
N
MMYEL
Y
SWOG
S1211 MM,High Risk, RVD+/-ELO
S1211
N
Other
Y
ALLIAN N1174 Bev +/- TRC105 in Bev Naïve GBM
CE
N1174
Y
ALLIAN Z11102 Breast Conserv. Surgery for MIBC
CE
Z11102
Y
ECOG-A E3108 CYP2D6 Activity&SingleAgTamox
E3108
II
BREAST Y
Y
SWOG
S1318 ALL, Age 65+, Ph±, Blinatumomab
S1318
N
Page
1
[comchr2.sql]
30 JAN 2015Southwest Oncology Group
Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center
Ca
Int Stat
Cntrl Temp
Phase Comm. grp Center Study
NCIPROTO
Study Close
------ ------ --- ------ ----------------------------------------- -------------- ----- ----CRIN
II
GI
N
S1310 Biliary,RefAdv,GSK1120212vsChemo
S1201
S1406
N
N
ALLIAN A021202 Carcinoid, Pazopanib vs Placebo
CE
A021202
Y
Y
ALLIAN C80803 Esoph, PET-directed combined Tx
CE
CALGB-80803
Y
Y
ECOG-A E2211 Panc, Adv, Temozolomide +/- Cape
CRIN
E2211
N
Y
ECOG-A E7208 CRC,Adv, Irino/Cet+/-Ramucirumab
CRIN
E7208
GU
Y
SWOG
S1314
LEUK
N
LUNG
LYMPH
Y
Y
SWOG
SWOG
Y
S1201 Gas/Esoph/GEJ, Adv, ERCC1-based
S1406 CRC,Met,BRAF mut,Irino+Cetux±Vem
N
S1314 Blad, COXEN Neoadj. Chemo + Cyst
S0919 Rel AML: Pravastatin+Ida+Ara-C
N
N
Y
ALLIAN C10701 Ph+ ALL, age 50+, Dasatinib+HCT
CE
CALGB-10701
N
Y
SWOG
S1300
N
Y
ALLIAN C30901 Mesothelioma, Maint. Pemtrxd
CE
CALGB-30901
N
Y
NRG
R1306 NSCLC,Adv,ALK/EGFR,TargetAgents
RTOG-1306
N
Y
SWOG
S1001 DLBCL, I-II, PET-Adapted Therapy
S1001
N
Y
ALLIAN C51101 CNS, myelo/non-myelo chemo, PhII
CE
CALGB-51101
Y
Y
ECOG-A E1411 MCL, RB+R, RBV+R, RB+LR, RBV+LR
E1411
Y
S1300 NSCLC,Adv,Alk+,Pem±Crizotinib
vs
Page
2
[comchr2.sql]
30 JAN 2015Southwest Oncology Group
Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center
Ca
Int Stat
Cntrl Temp
Phase Comm. grp Center Study
NCIPROTO
Study Close
------ ------ --- ------ ----------------------------------------- -------------- ----- ----CRIN
II
LYMPH
Y
ECOG-A E1412 DLBCL, R2CHOP vs RCHOP
CRIN
E1412
Y
NCIMET 9177 NHL, dose-adj. EPOCH+/-Rituximab
9177
Y
SWOG
S1320
Y
ECOG-A E2607 Dasatinib in KIT+ pts w/Melanoma
CRIN
E2607
MMYEL
Y
SWOG
S1304
N
OTHER
Y
ECOG-A E1311 HNSCC, Adj
CR
E1311
N
Y
ECOG-A E3311 Oroph,Srg + Low or Std IMRT
CRIN
E3311
Y
Y
ALLIAN N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX
CE
N1048
Y
Y
Y
Y
Y
SWOG
SWOG
SWOG
SWOG
S1400A
S1400B
S1400C
S1400D
N
N
N
N
MELAN
II-III GI
LUNG
III
BREAST N
S1320 Adv, BRAF mut, Inter v Contin
S1304 MM,relapsed/refractory, CAR+DEX
S1400A
S1400B
S1400C
S1400D
Afatinib vs Placebo
Non-Match: MEDI4736 vs Docetaxel
P13K: GDC-0032 vs Docetaxel
CDK4/6: Palbociclib v Docetaxel
FGFR: AZD4547 vs Docetaxel
S1222 Brst,Fulv. +/- Ever. +/- Anastr.
Y
Y
SWOG
SWOG
Y
Y
S1007 Breast,Adj,N1,Endocrine+/-Chemo
S1207 Brst,Adj,Endocrine+/-Everolimus
N
N
N
S1007
S1207
Y
Y
ALLIAN A011106 Breast, Neoadj, ALTERNATE study
CE
A011106
N
ALLIAN A011202 Breast, Nodal XRT +/- ALND
CE
A011202
Page
3
[comchr2.sql]
30 JAN 2015Southwest Oncology Group
Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center
Int
Phase Comm. grp
------ ------ --III
BREAST Y
Stat
Center Study
NCIPROTO
------ ----------------------------------------- -------------ECOG-A E2108 Early Local Tx for Int Prim Tum
E2108
CRIN
Ca
Cntrl Temp
Study Close
----- ----Y
Y
ECOG-A PACCT-1 Assess of Ca Clinical Tests
CRIN
PACCT-1
Y
Y
Y
Y
Y
NRG
NRG
NRG
NRG
NRG
NSABP-B-43
NSABP-B-47
NSABP-B-51
NSABP-B-52
RTOG-1005
Y
CCD
Y
ALLIAN A011104 Preoperative Breast MRI
CE
A011104
Y
GI
Y
ALLIAN C80702 Adj FOLFOX+Celecoxib or Placebo
CE
CALGB-80702
Y
ALLIAN C80802 HCC, Adv, Sorafenib+/- Doxorub
CE
CALGB-80802
Y
Y
NRG
NRG
R0848 Panc, Adj, Erlotinib v ChemoRT
R1010 Esoph,HER2,TrimodalTx+/-Trastu
RTOG-0848
RTOG-1010
Y
Y
Y
Y
Y
SWOG
SWOG
SWOG
S0931 Renal, EVEREST
S1011 Blad, Standard vs Extended LND
S1216 Pros Adv, ADT +/- TAK-700 or Bic
S0931
S1011
S1216
N
N
N
Y
ALLIAN A031201 CRMPC, Enza +/- (Abira + Predni)
CE
A031201
N
Y
ALLIAN C70807 Pros, MEAL Study
CE
CALGB-70807
Y
Y
ALLIAN C90203 Pros, Surgery +/- Neoadj Chemo
CE
CALGB-90203
Y
Y
ECOG-A E2810 Renal, Pazopanib vs Placebo
CRIN
E2810
Y
Y
NRG
RTOG-0534
Y
GU
B43 Breast, DCIS, HER2+, RT +/- Tras
B47 Chemo vs Chemo + Trastuzumab
B51 Breast, Regional Nodal XRT
B52 Breast, Neoadj TCHP +/- AI
R1005 RTOG-1005
R0534 Pros, PBRT +/- NC-STAD +/- PLNRT
Y
Y
Page
4
[comchr2.sql]
30 JAN 2015Southwest Oncology Group
Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center
Stat
Center
-----NRG
NRG
NRG
Ca
Cntrl Temp
Study
NCIPROTO
Study Close
----------------------------------------- -------------- ----- ----R0815 Pros, dose-esca. RT +/- ADT
RTOG-0815
Y
R0924 Pros, NADT+WPRT vs. NADT+P&SV RT
RTOG-0924
Y
R1115 Pros, (ADT + RT) +/- TAK-700
RTOG-1115
Y
Y
SWOG
S1203 AML, Age 18-60, 7+3/IA/IA+V
Y
Int
Phase Comm. grp
------ ------ --III
GU
Y
Y
Y
LEUK
LUNG
S1203
N
ALLIAN A041202 CLL,65+,Ben+Rtx vs Ibrut±Rtx
CE
A041202
N
Y
ECOG-A E1910 BCR-ABL-neg B ALL, blinatumomab
CRIN
E1910
N
Y
ECOG-A E1912 CLL, age 18-70, Ibrutinib vs FCR
CRIN
E1912
Y
Y
ECOG-A E2905 MDS, Len vs Len + Epo
CRIN
E2905
Y
ECOG-A E2906 AML,age 60+,Clo vs Dauno+Cy
CRIN
E2906
Y
Y
SWOG
S0819
N
Y
ALLIAN C140503 NSCL, Lobect v Sublobar resect
CE
CALGB-140503
Y
ALLIAN C30607 NSCL,Adv Main Sunitinib v Placbo
CE
CALGB-30607
Y
Y
ALLIAN C30610 SCLC, Thoracic RT
CE
CALGB-30610
Y
Y
ALLIAN C30801 NSCLC, Adv, Select COX-2 Inhib
CE
CALGB-30801
N
Y
ALLIAN N107C SRS vs WBRT on Resected Met Dz
CE
N107C
Y
Y
ECOG-A E5508 NSCL,Adv,Main Bev,Pem or Bev+Pem
CRIN
E5508
N
S0819 NSCLC, ADV, CHEMO/BEV +/-CET
Y
Page
5
[comchr2.sql]
30 JAN 2015Southwest Oncology Group
Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center
Ca
Int Stat
Cntrl Temp
Phase Comm. grp Center Study
NCIPROTO
Study Close
------ ------ --- ------ ----------------------------------------- -------------- ----- ----III
MELAN
Y
ECOG-A E1609 Mel,AdjIpilAntiCTLA4vsInterferon
CRIN
E1609
Y
MMYEL
Y
ECOG-A E1A11 MM, frontline, BLD vs CLD
CRIN
E1A11
Y
Y
ECOG-A E3A06 Lenalidomide vs Observation
CRIN
E3A06
Y
Y
ALLIAN A091105 Desmoid,
CE
A091105
Y
Y
ALLIAN N0574 N0574
CE
N0574
Y
ALLIAN N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC
CE
N0577
Y
ECOG-A E1305 E1305
CRIN
E1305
Y
ECOG-A E3F05 E3F05
CRIN
E3F05
Y
Y
Y
Y
NRG
NRG
NRG
NRG
G0258
G0261
R0920
R1016
GOG-0258
GOG-0261
RTOG-0920
RTOG-1016
Y
Y
Y
Y
PREV
Y
SWOG
S0820 ColrecStg0-3 Blind DFMO/Sulindac
S0820
Y
SXQOL
N
N
OTHER
Sorafenib vs Placebo
Endo, Adv, CDDP+RT->CP vs CP
OVAR, Adv, CP vs Ifosfamide + P
HN, ADV, POSTOP IMRT ± CETUXIMAB
Orophx,p16+,RT+Cis v RT+Cetuxmab
S1200 Breast,AI Joint Pain,Acupuncture
S1202 Duloxetine AI Joint Pain
Y
ALLIAN A221101 Glioma, Nuvigil/Placebo
CE
Y
SCUSF
Fatigue
SCUSF806 Breast, Adj, Cardiotoxicity
N
Y
Y
A221101
Y
SCUSF-0806
Y
Page
6
[comchr2.sql]
30 JAN 2015Southwest Oncology Group
Open and Temporarily Closed Studies: By Study Type, Committee, Intergroup, SWOG/Other Stat Center
Int
Phase Comm. grp
------ ------ --Y
Ca
Stat
Cntrl Temp
Center Study
NCIPROTO
Study Close
------ ----------------------------------------- -------------- ----- ----ECOG-A E2511
E2511
CR
Page
7
[comchr2.sql]
30 JAN 2015
SWOG
SWOG Coordinated Open Studies
sorted by Study Id
Phase III
Page
Accrual
Protocol
Accrual Open
Months
as of Current
Number
Study
Goal Stat/Date
Open 01Jan02 Accrual
---------------- ---------------------------------------- ------- ---------- ------ ------- ------S0819 S0819
NSCLC, ADV, CHEMO/BEV +/-CET (LUNG)
1700 T-07/15/09
66
1333
1333
Proj.
Annual
Accr.
Rate
-----0
[comchr3.sql]
Proj.
Study
Expected Duration
Closure (Years)
-------- -------> 15 Yrs > 15 Yrs
S0820 S0820
ColrecStg0-3 Blind DFMO/Sulindac (PREV)
1488 Y-03/01/13
22
38
38
S0931 S0931
Renal, EVEREST (GU)
1218 Y-04/01/11
45
1052
1052
428 May-2015
4.2
S1007 S1007
Breast,Adj,N1,Endocrine+/-Chemo (BREAST)
4000 Y-01/15/11
48
3217
3217
996 Oct-2015
4.8
S1011 S1011
Blad, Standard vs Extended LND (GU)
620 Y-08/01/11
41
403
403
130 Sep-2016
5.2
S1200
Breast,AI Joint Pain,Acupuncture (SXQOL)
228 Y-05/16/12
32
134
134
72 Apr-2016
4.0
S1202
Duloxetine AI Joint Pain (SXQOL)
294 Y-05/15/13
20
170
170
172 Sep-2015
2.4
S1203 S1203
AML, Age 18-60, 7+3/IA/IA+V (LEUK)
784 Y-02/08/13
23
548
548
422 Jul-2015
2.5
S1207 S1207
Brst,Adj,Endocrine+/-Everolimus (BREAST)
3500 Y-09/03/13
16
255
255
292 Feb-2026
12.5
S1216 S1216
Pros Adv, ADT +/- TAK-700 or Bic (GU)
1636 Y-03/01/13
22
609
609
356 Nov-2017
4.7
S1222
Brst,Fulv. +/- Ever. +/- Anastr. (BREAST
)
840 Y-05/09/14
8
32
32
46 > 15 Yrs > 15 Yrs
S1400A S1400A
Non-Match: MEDI4736 vs Docetaxel (LUNG)
400 Y-06/15/14
7
36
36
72 Jan-2020
Accrual goals assume studies are not terminated early as a
Studies may have accrual objectives specific to subsets of
Accrual rate is projected from accrual in the previous six
Expected closure dates are calculated for SWOG coordinated
1
36 > 15 Yrs > 15 Yrs
result of interim analysis.
patients and are not reflected in this report.
months for studies open at least three months.
studies that have been open at least three months.
5.6
30 JAN 2015
Phase III
SWOG
SWOG Coordinated Open Studies
sorted by Study Id
Page
2
[comchr3.sql]
Proj.
Proj.
Accrual
Annual
Study
Protocol
Accrual Open
Months
as of Current Accr. Expected Duration
Number
Study
Goal Stat/Date
Open 01Jan02 Accrual
Rate Closure (Years)
---------------- ---------------------------------------- ------- ---------- ------ ------- ------- ------ -------- --------
S1400B S1400B
P13K: GDC-0032 vs Docetaxel (LUNG)
420 Y-06/15/14
7
4
4
S1400C S1400C
CDK4/6: Palbociclib v Docetaxel (LUNG)
328 Y-06/15/14
7
13
13
S1400D S1400D
FGFR: AZD4547 vs Docetaxel (LUNG)
318 Y-06/15/14
7
4
4
Accrual goals assume studies are not terminated early as a
Studies may have accrual objectives specific to subsets of
Accrual rate is projected from accrual in the previous six
Expected closure dates are calculated for SWOG coordinated
8 > 15 Yrs > 15 Yrs
26 Feb-2027
12.7
8 > 15 Yrs > 15 Yrs
result of interim analysis.
patients and are not reflected in this report.
months for studies open at least three months.
studies that have been open at least three months.